Developmental Therapeutics Committee
The Development Therapeutics Committee is in a unique position to facilitate the creation of new types of cancer treatment trials that personalize therapy using predictive biomarkers and drug targets. Its role in the Group is to:
- Educate members about new treatments, drug targets, and biomarker technologies
- Provide a platform for disseminating scientific concepts that arise within the 12 cancer-type-oriented committees and working groups in the Therapeutic Studies Program
- Conduct correlative studies that explore variability in patients and tumors, with a treatment focus rather than a disease focus
The original concept for the landmark NCI-MATCH precision medicine cancer trial originated in this committee as part of a collaboration with researchers at the National Cancer Institute (NCI) and throughout the National Clinical Trials Network (NCTN).
This committee is heavily involved in ComboMATCH, the largest initiative of its kind to test genomically targeted combinations of cancer drugs. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) leads the overarching coordination effort. The Alliance for Clinical Trials in Oncology, Children's Oncology Group, ECOG-ACRIN, NRG Oncology, and SWOG Cancer Research Network lead the various treatment trials with funding from the NCI through the NCTN.
Developmental Therapeutics Committee
Chair
ComboMATCH Subcommittee
Chair
Genomics Subcommittee
Chair
Dr. Spencer is also Chair of the Clonal Hematopoiesis Working Group, part of the Genomics Subcommittee
Immunotherapeutics/CIMAC Subcommittee
CIMAC stands for Cancer Immune Monitoring and Analysis Centers
